Abemaciclib + Niraparib Tosylate Monohydrate
Phase 1CompletedDevelopment Stage
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
Jun 7, 2021 → Jun 20, 2025
About Abemaciclib + Niraparib Tosylate Monohydrate
Abemaciclib + Niraparib Tosylate Monohydrate is a phase 1 stage product being developed by Eli Lilly for Anatomic Stage I Breast Cancer AJCC v8. The current trial status is completed. This product is registered under clinical trial identifier NCT04481113. Target conditions include Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04481113 | Phase 1 | Completed |
Competing Products
13 competing products in Anatomic Stage I Breast Cancer AJCC v8
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Tamoxifen + Vorinostat | Merck | Phase 2 | 52 |
| Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib | Novartis | Phase 1/2 | 41 |
| Lutetium Lu 177 Dotatate | Novartis | Phase 2 | 52 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin | Amgen | Phase 1 | 32 |
| Sacituzumab Govitecan | Gilead Sciences | Phase 2 | 51 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen | Pfizer | Phase 2 | 51 |
| Abexinostat Tosylate + Fulvestrant + Palbociclib | Pfizer | Phase 1 | 32 |
| Aromatase Inhibition Therapy | Bristol Myers Squibb | Pre-clinical | 22 |
| Pelareorep + Retifanlimab | Incyte | Phase 2 | 49 |
| Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody | Imugene | Phase 1 | 25 |
| Neratinib | Puma Biotechnology | Phase 2 | 44 |
| Ivermectin + Balstilmab + Pembrolizumab | Agenus | Phase 1/2 | 33 |